Your Position:

Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media

2025.03.12

Recently,many mainstream media forwarded the "Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia" released by CISION PR on March 09, 2025, following are some news links:

AP NEWS、Market Watch、KTLA5、Seeking Alpha、PR Newswire

Zhejiang Doer Biologics Co.,Ltd.

Telephone:0571-28256206

Fax:0571-28256206

Email:bd@doerbio.com

Address:Floor 2,Building 3, Hexiang Science and Technology Center, Phase 3, Medicine Port Town, Qiantang New District, Hangzhou,Zhejiang Province

© 2016-2020 Zhejiang Doer Biologics Co.,Ltd. Copyright Record number:网站备案号：浙ICP备14037239号

Scan to follow us